MCKHealthcare · Medical DistributionThe 17 Wall Street analysts covering McKesson Corp. hold a median 12-month price target of $950 — +14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores McKesson Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own McKesson Corp. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on MCK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +14.9% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 July 2026 | Citigroup | Maintains | Buy | $945 → $1,000 |
| 21 July 2026 | TD Cowen | Maintains | Buy | $1,012 → $989 |
| 10 June 2026 | Barclays | Maintains | Overweight | — |
| 10 June 2026 | Barclays | Maintains | Overweight | $1,050 → $925 |
| 14 May 2026 | Citigroup | Maintains | Buy | — |
| 12 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 8 May 2026 | JP Morgan | Maintains | Overweight | — |
| 8 May 2026 | UBS | Maintains | Buy | — |
| 28 Apr 2026 | William Blair | Initiates | Outperform | — |
| 22 Apr 2026 | UBS | Maintains | Buy | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Apr 2026 | B of A Securities | Maintains | Buy | — |
| 18 Feb 2026 | Barclays | Maintains | Overweight | — |
| 10 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 5 Feb 2026 | Mizuho | Maintains | Neutral | — |
| 5 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 5 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 10 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 91% of US stocks
Cheaper than 99% of US stocks
Cheaper than 22% of US stocks
Higher than 44% of US stocks
Higher than 71% of US stocks
Higher than 7% of US stocks
Higher than 52% of US stocks
Higher than 50% of US stocks
Higher than 2% of US stocks
Higher than 77% of US stocks
Higher than 7% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| MCKMcKesson Corp. | $100.2B | 73 |
| CORCencora, Inc. | $60.4B | 48 |
| CAHCardinal Health, Inc. | $54.7B | 94 |
| HSICHenry Schein, Inc. | $9.8B | 78 |
| MDTMedtronic PLC* | $109.5B | 82 |
| HCAHCA Healthcare, Inc.* | $87.2B | 66 |
| ELVElevance Health, Inc.* | $83.5B | 62 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MCK appears on the weeks it earns a place.
Zacks previews McKesson's upcoming Q1 results, noting the company enters the period with focus on AI-driven efficiency, specialty momentum, and oncology growth, while pricing dynamics may temper revenues.
Why it matters — A MCK watcher would look to this preview for signs of how operational efficiency and specialty demand will offset potential pricing headwinds in the quarter.
Zacks Investment Research has published an article encouraging investors to look beyond McKesson's top-and-bottom-line estimates for the quarter ending June 2026 and examine key metric estimates for deeper insight into the company's performance.
Why it matters — The article directs McKesson watchers to consider detailed key metrics rather than just headline revenue and earnings figures when evaluating the company's quarterly performance.
McKesson (MCK) shares closed at $865.51 in the most recent trading session, representing a decline of 2.59% from the prior day even as the broader market gained.
Why it matters — A stock decline on a day when the broader market rose may signal company-specific headwinds or investor sentiment worth monitoring for McKesson watchers.
Zacks reported that McKesson lacks the key ingredients for a likely earnings beat in its upcoming report, despite expected earnings growth.
Why it matters — MCK watchers would care because the assessment suggests the company may fall short of market expectations in its next earnings report.
Zacks Investment Research published an article examining whether McKesson (MCK) is a buy as Wall Street analysts express optimism. The piece questions the importance of sell-side analyst recommendations in influencing stock prices.
Why it matters — MCK watchers would care because the article discusses the potential influence of analyst ratings on the company's stock price.
The 17 Wall Street analysts covering McKesson Corp. have a median 12-month price target of $950, with estimates ranging from $812 to $1,065. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering McKesson Corp., 14 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks McKesson Corp. 73 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, McKesson Corp. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +14.9% from the last close, and Ticker Nerd's factor model ranks McKesson Corp. 73 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering McKesson Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $812 to $1,065 over the next 12 months.
McKesson Corp. returned +18.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings.
The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Can AI-Driven Efficiency and Specialty Demand Boost MCK's Q1 Results?". Zacks previews McKesson's upcoming Q1 results, noting the company enters the period with focus on AI-driven efficiency, specialty momentum, and oncology growth, while pricing dynamics may temper revenues.
McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings. Its pharmaceutical distribution business supplies branded, generic, specialty, biosimilar, and over-the-counter products, while its medical-surgical operations provide clinical supplies, logistics, and equipment support. McKesson also offers technology-enabled services that help healthcare organizations manage prescriptions, practice operations, and patient care workflows. Through its broad distribution network and service platforms, McKesson plays a central role in connecting manufacturers, providers, and pharmacies across the U.S. and internationally.
CEO Mr. Brian S. Tyler Ph.D. · 41,600 employees · United States · https://www.mckesson.com